Analyst Price Targets — SIBN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 4, 2026 12:18 pm | Patrick Wood | UBS | $25.00 | $18.65 | TheFly | SI-Bone price target raised to $25 from $24 at UBS |
| July 28, 2026 10:47 am | Patrick Wood | UBS | $24.00 | $17.05 | TheFly | SI-Bone initiated with a Buy at UBS |
| July 16, 2026 2:07 pm | — | Truist Financial | $21.00 | $17.92 | TheFly | SI-Bone price target raised to $21 from $18 at Truist |
| February 24, 2026 12:24 pm | — | Truist Financial | $24.00 | $15.62 | TheFly | SI-Bone price target raised to $24 from $23 at Truist |
| December 18, 2025 2:15 pm | — | Truist Financial | $23.00 | $19.62 | TheFly | SI-Bone price target raised to $23 from $21 at Truist |
| December 17, 2025 12:28 pm | William Plovanic | Canaccord Genuity | $27.00 | $19.42 | TheFly | SI-Bone price target raised to $27 from $26 at Canaccord |
| December 16, 2025 11:46 am | David Saxon | Needham | $27.00 | $19.16 | StreetInsider | SI-BONE Inc. (SIBN) PT Raised to $27 at Needham, Added To Conviction List |
| December 2, 2025 11:36 am | — | Morgan Stanley | $23.00 | $18.87 | TheFly | SI-Bone price target raised to $23 from $20 at Morgan Stanley |
| October 15, 2025 12:46 pm | Richard Newitter | Truist Financial | $20.00 | $15.27 | TheFly | SI-Bone price target lowered to $20 from $22 at Truist |
| August 11, 2025 11:10 am | Ross Osborn | Cantor Fitzgerald | $25.00 | $15.68 | StreetInsider | Cantor Fitzgerald Reiterates Overweight Rating on SI-BONE Inc. (SIBN) |
Latest News for SIBN
SANTA CLARA, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming 2026 Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY. Management will be hosting a fireside chat on Monday, September 14,…
Does Si-Bone (SIBN) have what it takes to be a top stock pick for momentum investors? Let's find out.
The mean of analysts' price targets for Si-Bone (SIBN) points to a 25.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
The consensus price target hints at a 38.6% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
SiBone (NASDAQ: SIBN) reported second-quarter 2026 revenue growth of 15.2% and narrowed its net loss as procedure volumes increased across its U.S. business and international demand rose for its expanded product portfolio. Worldwide revenue reached $56 million for the quarter ended June 30, while U.S. revenue increased 14.7% to $53.2 million. International revenue grew 25.9% to
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SIBN.
U.S. House Trading
No House trades found for SIBN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.